Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.
2 reports, 1 independent
Updated Sep 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
- FDA
-
Nasdaq
American fully electronic stock exchange
Related events
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- An unnamed company secured regulatory approval in July 2025, leading to a $2.5 million milestone reported today.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.